Back to Search
Start Over
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
- Publication Year :
- 2020
-
Abstract
- The hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is defined by germline mutations in the fumarate hydratase (FH) gene and associated with leiomyomas and aggressive renal cell carcinomas with FH deficiency. Here, we comprehensively characterize two new patients with HLRCC syndrome on a morphological, immunohistochemical and genetic level. The patients developed aggressive HLRCC syndrome-associated RCCs, uterine leiomyomas and dermal leiomyomas. One HLRCC syndrome-associated RCC exhibited an unusual morphology with accumulation of "colloid-like" cytoplasmic inclusions, which might serve as a novel sentinel feature to trigger further testing. This case showed partially retained FH expression, initially hampering correct diagnosis. Comprehensive next-generation sequencing analyses of HLRCC syndrome-associated RCC and leiomyomas in our patients revealed divergent genetic changes in the FH gene in different tumors from the same patient. While all leiomyomas (uterine and cutaneous) showed a FH loss of heterozygosity (LOH) as a wildtype allele inactivating event, one HLRCC-RCC showed a second, undescribed NM_000143.3; c.947C>T; p.Ala316Val FH mutation accompanying the preexisting splice site mutation c.378+2T>C. In the other HLRCC syndrome-associated RCC, the FH mutation (NM_000143.3; c.462T>G; p.Asn154Lys with a somatic LOH) represents another variant of unknown significance that we link to HLRCC - and thus classify as likely pathogenic. Due to the specific diagnosis of metastatic HLRCC syndrome-associated RCC, both cases were treated in first line with bevacizumab/erlotinib and showed remarkable and long lasting responses. These findings allow new morphological and molecular insights into the biology of the HLRCC syndrome, corroborate the "second hit" hypothesis of tumor formation in HLRCC patients and may promote a distinct therapeutic approach.
- Subjects :
- Cancer Research
Skin Neoplasms
10039 Institute of Medical Genetics
Mutation, Missense
Antineoplastic Agents
610 Medicine & health
Biology
urologic and male genital diseases
medicine.disease_cause
Fumarate Hydratase
Loss of heterozygosity
Erlotinib Hydrochloride
03 medical and health sciences
0302 clinical medicine
Germline mutation
1311 Genetics
Neoplastic Syndromes, Hereditary
Renal cell carcinoma
Leiomyomatosis
10049 Institute of Pathology and Molecular Pathology
Antineoplastic Combined Chemotherapy Protocols
Genetics
medicine
Humans
1306 Cancer Research
Allele
neoplasms
Mutation
Splice site mutation
10042 Clinic for Diagnostic and Interventional Radiology
Middle Aged
medicine.disease
female genital diseases and pregnancy complications
Bevacizumab
10062 Urological Clinic
030220 oncology & carcinogenesis
Uterine Neoplasms
10032 Clinic for Oncology and Hematology
Cancer research
Immunohistochemistry
Female
Hereditary leiomyomatosis and renal cell carcinoma
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....7f091f3aca818d18a1304906a7b2e638